TrumpRx Asks You to Choose: Insurance or Cheaper Drugs. You Can’t Have Both.

Federal Portal Launches in 2026

Americans pay almost three times more for prescription drugs than people in other wealthy countries.

About one in four say they struggle to afford their medications, and millions have skipped doses or rationed pills to save money.

The Trump administration says it has a fix: a federal website called TrumpRx that will launch in early 2026 and show Americans where to buy brand-name drugs at steep discounts, but only if they pay cash and skip their insurance entirely.

Fourteen major pharmaceutical companies have already signed on, and the deals include some of the most expensive medications in America.

Drug Prices Triple Other Countries

Prescription drug prices in the United States are significantly higher than in other nations, with prices averaging 2.78 times those seen in 33 other countries.

For brand-name drugs specifically, U.S. prices are at least 3.22 times higher than prices in comparison countries.

In 2023, the U S. spent over $600 billion on prescription medications, more than any other country on a per-person basis. The gap comes down to how the system works: unlike peer nations, the U.S. does not impose direct price controls, and a web of middlemen adds costs at every step.

The Portal Is a Search Engine

TrumpRx is a federal government initiative centered around a new website slated to launch in early 2026. The government-operated website will not directly sell or distribute medications.

Instead, it’s designed to function as a search portal where consumers can look up their prescriptions and, if a drug is part of the program, they will be redirected to the pharmaceutical manufacturer’s own direct-to-consumer platform to complete the purchase.

This keeps the government out of the complicated business of actually shipping pills to people’s doors.

Pfizer Made the First Deal

On September 30, 2025, Pfizer became the first major pharmaceutical company to publicly agree to the administration’s framework.

In a statement, Pfizer officials said primary care treatments and some select specialty brands will be offered at savings that will range as high as 85% and on average 50%.

The deal was announced in the Oval Office with President Trump and Pfizer CEO Albert Bourla, and it came with a three-year exemption from pharmaceutical tariffs the administration had threatened.

Fourteen Companies Have Signed On

14 of the 17 companies previously called out by the President for drug prices have announced deals with the administration to offer discounted medication on TrumpRx.

Pharmaceutical companies Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi joined earlier agreements with Pfizer, AstraZeneca, EMD Serono, Novo Nordisk and Eli Lilly.

All future drug releases from these companies will also be available at most-favored-nation pricing through TrumpRx.

Weight Loss Drugs Drop to $350

The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through TrumpRx.

The average monthly cost of weight loss injections on TrumpRx is expected to start around $350 and fall to about $250 within the next two years, President Trump said when announcing the arrangements.

Starting doses of upcoming obesity pills from Eli Lilly and Novo Nordisk will be $149 per month for everyone getting them through Medicare, Medicaid or TrumpRx.

Medicare Covers Obesity Drugs Now

Medicare will cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time. Medicare beneficiaries will pay a copay of $50 per month.

The agreements will cut prices of GLP-1 drugs for Medicare and Medicaid beneficiaries in 2026. This is a major shift, because Medicare has been prohibited from covering weight loss medications for years.

Blood Thinner Goes Free on Medicaid

Bristol Myers Squibb announced an agreement with the U.S. government to provide Eliquis, an oral anticoagulant relied upon by millions of Americans daily, for free to the Medicaid program starting January 1, 2026.

Known as Eliquis, it is the company’s top prescribed drug as well as being one of Medicaid’s most widely-used medicines.

The company will also donate more than seven tons of the drug’s active ingredient to a national strategic reserve.

Mark Cuban Partners With TrumpRx

Online pharmacy Cost Plus Drugs will be participating in TrumpRx, according to Cost Plus founder Mark Cuban.

Cost Plus Drugs, which sells certain prescription medications directly to consumers at cost plus a 15% markup, is sharing access to its application programming interface so that TrumpRx can pull price data.

Cuban called it a chance to boost visibility: “Because as our volumes go up, our costs go down. And when our costs go down, the price for patients go down.”

Insured Patients May See No Savings

TrumpRx is a cash-pay channel. Even with advertised discounts, prices may still exceed what many insured members with copays can afford.

Insurance policies are unlikely to count cash-pay transactions outside the benefit towards plan deductible or out-of-pocket balances.

That means if you buy through TrumpRx, those purchases will not help you reach the point where your insurance kicks in more coverage. For the 92% of Americans with insurance, the old system may still be cheaper.

Middlemen Drive Up Drug Costs

PBMs serve as middlemen, negotiating the terms and conditions for access to prescription drugs for hundreds of millions of Americans.

Due to decades of mergers and acquisitions, the three largest PBMs now manage nearly 80 percent of all prescriptions filled in the United States.

Consumers can benefit from lower prices, but PBMs themselves can benefit more than consumers do in cases where drugmakers start their negotiations with a high initial offer.

TrumpRx bypasses these middlemen entirely for cash-paying customers.

The Limits of Cash-Only Savings

The portal represents a new option for Americans without insurance or those facing sky-high deductibles, especially for expensive medications that cost more out-of-pocket than the TrumpRx discounts.

Health policy experts question whether TrumpRx will materially lower average U.S.

drug spending without parallel benefit-design changes, since many insured patients already have low point-of-sale costs.

Still, for the uninsured diabetic paying $1,000 a month for Ozempic or the cancer patient rationing pills, a 50% discount could be the difference between taking their medication and skipping it.

This article was created with AI assistance and human editing.

Read more from this brand:

• Trump’s Plan Could Kill Nursing Schools, 140 Lawmakers Warn
• Medicare Will Require Facial Recognition to Log In Starting in 2026
• Hospitals Could Lose All Federal Funding for Treating Trans Kids